Related Experiment Video

Updated: Aug 20, 2026

The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

[Anti-mutagenesis effects of total flavonoids of Astragalus]

De-qing Wang1, Ya-ping Tian, Shu-zhen Song

  • 1Department of Biochemistry, PLA General Hospital, Beijing 100853, China. deqingw@vip.sina.com

Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica
|December 25, 2004
PubMed
Abstract

Insights

Total flavonoids of Astragalus (TFA) showed significant antimutagenesis effects. High concentrations of TFA reduced cyclophosphamide-induced genotoxicity and gene mutations in V79/HGPRT cells.

Area of Science:

  • Pharmacology
  • Toxicology
  • Natural Products

Background:

  • Mutagenesis poses a significant health risk.
  • Natural compounds are explored for chemopreventive properties.
  • Astragalus species are traditionally used in medicine.

Purpose of the Study:

  • To evaluate the antimutagenic potential of total flavonoids of Astragalus (TFA).
  • To assess the protective effects of TFA against chemically induced mutations in vitro and in vivo.

Main Methods:

  • In vitro and in vivo assays were employed.
  • Miconucleolus assay, semen teratogenesis test, and V79/HGPRT gene mutation assay were performed.
  • Different concentrations of TFA were tested against mutagens like cyclophosphamide and mitomycin C.

Main Results:

  • TFA did not impact the body weight of experimental mice.
  • High concentrations of TFA significantly reduced cyclophosphamide-induced micronucleus formation and V79/HGPRT gene mutations.
  • TFA did not show a statistically significant effect on mitomycin C-induced semen teratogenesis.

Conclusions:

  • Total flavonoids of Astragalus exhibit a notable antimutagenic effect.
  • TFA demonstrates potential as a protective agent against specific types of genotoxicity.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...